Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  Google Scholar 

Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C (2017) Progress and prospects of early detection in lung cancer. Open Biol 7(9):1–12. https://doi.org/10.1098/rsob.170070

Article  CAS  Google Scholar 

Bracht JWP, Karachaliou N, Berenguer J, Pedraz-Valdunciel C, Filipska M, Codony-Servat C, Codony-Servat J, Rosell R (2019) Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). Int J Biol Sci 15(12):2607–2614. https://doi.org/10.7150/ijbs.32889

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol 4(11):1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969

Article  PubMed  Google Scholar 

Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015) Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16(4):e165-172. https://doi.org/10.1016/s1470-2045(14)71180-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S, Rauch J, Kolch W (2020) Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 21(3):1102. https://doi.org/10.3390/ijms21031102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, Yang X (2018) Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis 9(2):129. https://doi.org/10.1038/s41419-017-0120-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen B, Lai J, Dai D, Chen R, Liao N, Gao G, Tang H (2020) PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. Ther Adv Med Oncol 12:1758835920974212. https://doi.org/10.1177/1758835920974212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding L, Chen X, Xu X, Qian Y, Liang G, Yao F, Yao Z, Wu H, Zhang J, He Q, Yang B (2019) PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3. Cancer Immunol Res 7(1):136–149. https://doi.org/10.1158/2326-6066.Cir-18-0071

Article  CAS  PubMed  Google Scholar 

Dellomo AJ, Abbotts R, Eberly CL, Karbowski M, Baer MR, Kingsbury TJ, Rassool FV (2022) PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. Transl Oncol 15(1):101283. https://doi.org/10.1016/j.tranon.2021.101283

Article  CAS  PubMed  Google Scholar 

Fang Z, Gong C, Ye Z, Wang W, Zhu M, Hu Y, Liu Z, Zhou W, Li H (2022) TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1. DNA Repair 111:103278. https://doi.org/10.1016/j.dnarep.2022.103278

Article  CAS  PubMed  Google Scholar 

de Souza França PD, Guru N, Kostolansky AR, Mauguen A, Pirovano G, Kossatz S, Roberts S, Abrahão M, Patel SG, Park KJ, Reiner T, Jewell E (2021) PARP1: a potential molecular marker to identify cancer during colposcopy procedures. J Nucl Med 62(7):941–948. https://doi.org/10.2967/jnumed.120.253575

Article  CAS  PubMed  Google Scholar 

Montaldi AP, Lima SCG, Godoy P, Xavier DJ, Sakamoto-Hojo ET (2020) PARP-1 inhibition sensitizes temozolomide-treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncol Rep 44(5):2275–2287. https://doi.org/10.3892/or.2020.7756

Article  CAS  PubMed  Google Scholar 

Wang Q, Xiong J, Qiu D, Zhao X, Yan D, Xu W, Wang Z, Chen Q, Panday S, Li A, Wang S, Zhou J (2017) Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. Int J Biochem Cell Biol 92:164–172. https://doi.org/10.1016/j.biocel.2017.08.001

Article  CAS  PubMed  Google Scholar 

Zhang Z, Lian X, Xie W, Quan J, Liao M, Wu Y, Yang ZZ, Wang G (2020) Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Sci Rep 10(1):20924. https://doi.org/10.1038/s41598-020-77908-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erguven M, Bilir A, Yazihan N, Ermis E, Sabanci A, Aktas E, Aras Y, Alpman V (2011) Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int 11(1):18. https://doi.org/10.1186/1475-2867-11-18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong Y, Wang R, Liu X, Tian M, Wang Y, Cui Y, Zou W, Zhao Y (2021) Zuojin pill ameliorates chronic atrophic gastritis induced by MNNG through TGF-β1/PI3K/Akt axis. J Ethnopharmacol 271:113893. https://doi.org/10.1016/j.jep.2021.113893

Article  CAS  PubMed  Google Scholar 

Jeong KY, Park MH (2021) The significance of targeting poly (ADP-ribose) polymerase-1 in pancreatic cancer for providing a new therapeutic paradigm. Int J Mol Sci 22(7):3509. https://doi.org/10.3390/ijms22073509

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engbrecht M, Mangerich A (2020) The nucleolus and PARP1 in cancer biology. Cancers (Basel) 12(7):1813. https://doi.org/10.3390/cancers12071813

Article  CAS  PubMed  Google Scholar 

Yamashita S, Tanaka M, Ida C, Kouyama K, Nakae S, Matsuki T, Tsuda M, Shirai T, Kamemura K, Nishi Y, Moss J, Miwa M (2022) Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation. Exp Cell Res 417(1):113163. https://doi.org/10.1016/j.yexcr.2022.113163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi EB, Yang AY, Kim SC, Lee J, Choi JK, Choi C, Kim MY (2016) PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair. Oncogene 35(35):4569–4579. https://doi.org/10.1038/onc.2016.3

Article  CAS  PubMed  Google Scholar 

Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H (2019) Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity. Cell Rep 27(12):3422-3432.e3424. https://doi.org/10.1016/j.celrep.2019.05.058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Wang Y, Wu H, Zhou S, Li S, Meng X, Tao R, Yu J (2022) Olaparib combined with dacomitinib in osimertinib-resistant brain and leptomeningeal metastases from non-small cell lung cancer: a case report and systematic review. Front Oncol 12:877279. https://doi.org/10.3389/fonc.2022.877279

Article  PubMed  PubMed Central  Google Scholar 

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):26. https://doi.org/10.1186/s12943-019-0954-x

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Zhou Y, Jiang L, Lu L, Dai T, Li A, Chen Y, Zhang L (2021) CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway. Mol Cancer 20(1):43. https://doi.org/10.1186/s12943-021-01332-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Jia L, Sun Y, Li C, Zhang L, Wang X, Chen H (2021) CORO1C is associated with poor prognosis and promotes metastasis through PI3K/AKT pathway in colorectal cancer. Front Mol Biosci 8:682594. https://doi.org/10.3389/fmolb.2021.682594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu MD, Zhang YY, Yi SY, Sun BB, Lan J, Jiang HM, Hao GP (2022) Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells. J Cell Mol Med 26(5):1606–1620. https://doi.org/10.1111/jcmm.17202

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30(Suppl_10):x12–x20. https://doi.org/10.1093/annonc/mdz381

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong C, Wu J, Chen Y, Nie J, Chen C (2021) Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 12:628690. https://doi.org/10.3389/fphar.2021.628690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Xia X, Chen K, Chen M, Meng Y, Lv D, Yang H (2021) Reduced PHLPP expression leads to EGFR-TKI resistance in lung cancer by activating PI3K-AKT and MAPK-ERK dual signaling. Front Oncol 11:665045. https://doi.org/10.3389/fonc.2021.665045

Article  CAS  PubMed